Embio Ltd. is a leading global manufacturer specialising in controlled substances, advanced intermediates, and chiral molecules.

With over 30 years of expertise, Embio Ltd. has established itself as a pioneer in bacterial, fungal, and GMO biotransformation technologies. The company focuses on backward-integrated GMO platforms and leverages disruptive technologies to achieve a leadership position in the global market. Embio operates a state-of-the-art facility in Mahad, India, approved by US-FDA and other international regulators, ensuring top-quality manufacturing for regulated markets. Their clientele spans over 70 countries, including top-tier pharmaceutical companies.

Technology and innovation is the backbone of Embio’s success, which allows us to achieve a leadership position as a manufacturer of Active Pharmaceutical Ingredients (APIs), Intermediates and Speciality chemicals catering to a range of global customers in the pharmaceutical, nutraceutical, food, cosmetic, crop & plant protection segments. With 30+ years of experience in handling bacterial, fungal & Category 1 GMO bio-transformation, Embio has demonstrated an impeccable track record in creating sustainable, environmental friendly and disruptive technologies. With licenses to manufacture Schedule-1 & Schedule-2 substances, Embio is a leading global player in the domain of controlled substances, advanced intermediates & chiral molecules. Embio’s State of the Art manufacturing facility is approved by US-FDA, PMDA, KFDA, COFEPRIS & WHO-GMP. Our products & services cater to the stringent requirements of a large customer base in more than 70 countries, with a major share from regulated markets that includes originator and large multi-national companies.